Psychedelic-assisted Group Program for First Responders

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

January 1, 2025

Primary Completion Date

July 1, 2025

Study Completion Date

September 1, 2025

Conditions
PsilocybinPsychotherapy, Group
Interventions
DRUG

Psilocybin

Psilocybin in the study comes in the form of the study drug, PYEX. PYEX is a drug substance which is a partially purified fraction of the extract of Psilocybe cubensis mushroom fruiting bodies. It is a mixture of indole alkaloids, other mushroom fruiting body components and stabilization excipients. The major indole alkaloids present include psilocybin and psilocin (dephosphorylated psilocybin). PEX010 is a capsule for oral administration and is manufactured with PYEX (12.5-14.0% psilocybin), excipients, and HPMC (hydroxypropyl methyl cellulose) capsules.

Trial Locations (1)

V3V 0C6

RECRUITING

Centre for Neurology Studies, Surrey

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Empower Psychedelics

UNKNOWN

collaborator

Centre for Neurology Studies, Canada

UNKNOWN

collaborator

Mitacs

INDUSTRY

lead

Empower Research Inc

INDUSTRY